Initial Case Quality Control Form Mesothelioma (MESO)

Inst	Instructions: This form should be completed for all cases submitted for TCGA, prior to the shipment of samples to the BCR.											
	Questions regarding this form should be directed to the Tissue Source Site's primary Clinical Outreach Contact at the BCR.											
repo	Tissue Source Site (TSS) acknowledges that the Biospecimen Core Resource (BCR) may confirm that the diagnosis of the frozen biospecimen is consistent with the primary diagnosis reported by the TSS through histopathology examination in the BCR laboratory. If the BCR identifies a possible discrepancy, the TSS authorizes the BCR to report these patient results to the TSS by means of a formal report in confidential email format for the quality assurance program of the TSS to address.											
Tissu												
	Has this TSS received permission from the NCI to provide time intervals as a substitute for requested dates on this form? 🗆 Yes 🛛 No											
	Note: Provided time intervals must begin with the date of initial pathologic diagnosis.											
Tum	nor Information: The following	sections are to be provided by a Pathologist										
#												
1	Histologic Subtype of Tumor Submitted for TCGA	 Diffuse malignant mesothelioma - Epithelioid Diffuse malignant mesothelioma - Sarcomatoid Diffuse malignant mesothelioma - Desmoplastic Diffuse malignant mesothelioma - Biphasic Diffuse malignant mesothelioma, NOS 	Indicate the confirmed diagnosis of the tumor submitted for TCGA. 3081934									
2	Tumor Type	□ Primary (primary untreated malignant biospecimen)	Indicate the type of tumor submitted for TCGA. 3288124 All submitted biospecimens should NOT have systemic treatment prior to procurement.									
3	Anatomic Site of Frozen Biospecimen	🗆 Pleura	Indicate the anatomic site of the frozen tumor biospecimen submitted for TCGA. 3081961									
4	Other Site of Disease		If the submitted tissue was a distant metastasis, indicate the location of the tumor. 2584114									
5	Was pleurodesis performed prior to cancer sample procurement?	□ Yes □ No □ Unknown	Indicate whether the patient received pleurodesis prior to the resection of the tumor submitted for TCGA. 3646078									
6	If pleurodesis was performed, was it performed at least 90 days prior to the cancer sample procurement?	d Ves D No Unline ourp d Set 16 the patient received pleurodesis, indicate whether the procedure was performed at least 90 days prior to the resection of the tumor sample submitted for TCGA. 3646080										
7	Month Pleurodesis was Performed		If the patient received pleurodesis, provide the month the procedure was performed. 3646090									
8	Day Pleurodesis was	01 02 03 04 05 06 07 08 09 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31	If the patient received pleurodesis, provide the day the procedure was performed. 3646083									
9	Year Pleurodesis was Performed		If the patient received pleurodesis, provide the year the procedure was performed. 3646091									
10	Month of Cancer Sample Procurement		Provide the month of the procedure performed to obtain the malignant tissue submitted for TCGA. 3008197									

Initial Case Quality Control Form Mesothelioma (MESO)

#	Question	Entry Alternatives 0 01 0 03 0 04 0 05 0 06 0 07 0 08 0 09 0 11 0 12	Working Instructions Provide the day of the procedure performed to obtain							
11	Day of Cancer Sample Procurement	$\begin{array}{cccccccccccccccccccccccccccccccccccc$	the malignant tissue submitted for TCGA. 3008195							
12	Year of Cancer Sample Procurement		Provide the year of the procedure performed to obtain the malignant tissue submitted for TCGA. 3008199							
13	Method of Cancer Sample Procurement	 Thoracoscopic Biopsy Open Surgery Other Method, (please specify) 	Indicate the procedure performed to obtain the malignant tissue submitted for TCGA. 3103514							
14	Other Method of Cancer Sample Procurement		If the procedure performed to obtain the malignant tissue is not included in the provided list, specify the procedure. 2006730							
15	Country Where Cancer Sample was Procured		Provide the country where the tissue submitted for TCGA was procured. 3203072							
16	Race	 American Indian or Alaska Native A person having origins in any of the original peoples of North and South America (including Central America), and who maintains tribal affiliation or community attachment. Asian A person having origins in any of the original peoples of the far East, Southeast Asia, or in the Indian subcontinent including, for example, Cambodia, China, India, Japan, Korea, Malaysia, Pakistan, the Philippine Islands, Thailand, and Vietnam. White 	Provide the patient's race using the defined categories. 2192199							
17	Ethnicity	 Not Hispanic or Latino A person not meeting the definition of Hispanic or Latino. Hispanic or Latino A person of Mexican, Puerto Rican, Cuban, Central or South American or other Spanish culture or origin, regardless of race. Not Evaluated Not provided or available. Unknown	Provide the patient's ethnicity using the defined categories. 2192217							
18	Vessel Used	□ Cryovial □ Cassette □ Other, specify □ Biospecimen Storage Bag □ Cryomold	Indicate the type of vessel used to ship the tissue to the Biospecimen Core Resource (BCR) for TCGA. 3081940							
19	Other Vessel Used		If the vessel used to ship the tissue to the BCR is not included in the provided list, specify the vessel used. 3288137							

Initial Case Quality Control Form Mesothelioma (MESO)

#	Question	Entry Alternatives	Working Instructions
20	Is tumor sample being submitted for Laser Cryo- Enrichment (LCE)?	□ Yes □ No	Indicate whether the tumor sample submitted to the BCR is intended to undergo Laser Cryo-Enrichment (LCE) after the BCR receives the sample. 3288488
21	Was sample prescreened at site?	□ Yes □ No	Indicate whether the sample submitted to the BCR was prescreened at the TSS. 3081942
Tur	nor Slides Submitted		
<u>22</u>	Types of Slides Submitted	 Physical Top Slide Digital Top Slide Image Physical FFPE Slide Digital FFPE Slide Image 	Indicate the type(s) of slide(s) submitted to the BCR. <u>TBD</u> Top Slide Definition: Slide cut directly from frozen biospecimen = mirror image of inked surface
<u>23</u>	Slide/Digital Image ID #		Provide the slide ID for each slide (physical and digital image) submitted to the BCR. 2321277
Tun	or Information: If submitting	multiple pieces of the same primary tumor for this case, complete the following informat	ion for each piece of tumor sent to the BCR.
<u>24</u>	Tumor Identifier		Provide the TSS unique tumor ID. If multiple pieces of tumor are submitted, each tumor needs a unique ID. 3288096
<u>25</u>	Weight of Frozen Tumor	(mg) (0.2cm ³ (0.6cm * 0.6cm)) = ~200mg	Provide the weight of the tumor sample submitted for TCGA. 3081946 Weight can be estimated based on the size of the tumor submitted.
<u>26</u>	Tumor Nuclei %	(%)	Provide the percent of tumor nuclei for the sample submitted for TCGA. 2841225 Check with the BCR to confirm the current acceptable TCGA metrics.
<u>27</u>	Necrosis %	(%)	Provide the percent of necrosis for the sample submitted for TCGA. 2841237 Check with the BCR to confirm the current acceptable TCGA metrics.
Nori	mal Information: A normal con	ntrol must be present to qualify.	
28	Type(s) of Normal Control Check all that apply	Image: Whole Blood Image: Extracted DNA from Blood Image: Buffy Coat Image: Non-Neoplastic Control Tissue* Image: Lymphocytes Image: Non-Neoplastic Control Tissue*	Indicate the type of normal control submitted for this case. 3081936 *Non-neoplastic Control Tissue may only be submitted with NCI
Nor	mal Control: Whole Blood		approval.
<u>29</u>	Method of Normal Sample Procurement	D Blood Draw	Indicate the procedure performed to obtain the normal control sample submitted for TCGA. 3288147
<u>30</u>	Month of Normal Sample Procurement		Provide the month of the procedure performed to obtain the normal control submitted for TCGA. 3288195
<u>31</u>	Day of Normal Sample Procurement	$\begin{array}{c ccccccccccccccccccccccccccccccccccc$	Provide the day of the procedure performed to obtain the normal control submitted for TCGA. 3288196

Initial Case Quality Control Form Mesothelioma (MESO)

#	Question		Entry Alternatives		Working Instructions						
<u>32</u>	Year of Normal Sample Procurement				Provide the year of the procedure performed to obtain the normal control submitted for TCGA. 3288197						
<u>33</u>	Normal Identifier		Provide the TSS unique normal ID. If multiple normal control samples are submitted, each normal control needs a unique ID. 3288138								
Nor	Normal Control: Buffy Coat/ Lymphocytes										
<u>34</u>	Normal Control Type	Buffy Coat Lymphocytes			Indicate the type of normal control submitted for TCGA. 3081936						
<u>35</u>	Method of Normal Sample Procurement	Blood Draw			Indicate the procedure performed to obtain the normal control sample submitted for TCGA. 3288147						
<u>36</u>	Month of Normal Sample Procurement				Provide the month of the procedure performed to obtain the normal control submitted for TCGA. 3288195						
<u>37</u>	Day of Normal Sample Procurement	3 🗆 14 🗆 15 🗆 16 🖸	$ \begin{array}{cccccccccccccccccccccccccccccccccccc$		Provide the day of the procedure performed to obtain the normal control submitted for TCGA. 3288196						
<u>38</u>	Year of Normal Sample Procurement				Provide the year of the procedure performed to obtain the normal control submitted for TCGA. 3288197						
<u>39</u>	Normal Identifier				Provide the TSS unique normal ID. If multiple normal control samples are submitted, each normal control needs a unique ID.						
Nor	mal Control: Extracted DNA fi	Blood									
<u>40</u>	Method of Normal Sample Procurement	Blood Draw			Indicate the procedure performed to obtain the normal control sample submitted for TCGA. 3288147						
<u>41</u>	Month of Normal Sample Procurement	1 🗆 02 🗆 03 🗆 04 🛛			Provide the month of the procedure performed to obtain the normal control submitted for TCGA. 3288195						
<u>42</u>	Day of Normal Sample Procurement	3 🗆 14 🗆 15 🗆 16 🛛	05 06 07 08 09 17 18 19 20 21 29 30 31		Provide the day of the procedure performed to obtain the normal control submitted for TCGA. 3288196						
<u>43</u>	Year of Normal Sample Procurement				Provide the year of the procedure performed to obtain the normal control submitted for TCGA. 3288197						
<u>44</u>	Normal Identifier				Provide the TSS unique normal ID. If multiple normal control samples are submitted, each normal control needs a unique ID. 3288138						
<u>45</u>	Extracted DNA Quantity	_	(µg)		Provide the quantity (μ g) of the normal control sample sent to the BCR for TCGA. 3288185						
<u>46</u>	Extracted DNA Quantification Method			Provide the quantification method of the normal control sample sent to the BCR for TCGA. 3288186							
<u>47</u>	Extracted DNA Concentration		(µg/µL)		Provide the concentration (μ g/ μ L) of the normal control sample sent to the BCR for TCGA. 3288187						

Initial Case Quality Control Form Mesothelioma (MESO)

#	Question	Entry Alternatives	Working Instructions									
<u>48</u>	Extracted DNA Volume	(µL)	Provide the volume (μL) of the normal control sample sent to the BCR for TCGA. 3288188									
Nor	Normal Control: Non-Neoplastic Control Tissue											
<u>49</u>	Method of Normal Sample Procurement	□ Blood Draw□ Excisional Biopsy□ Fine Needle Aspiration□ Tumor Resection□ Incisional Biopsy□ Other Method (please specify)	Indicate the procedure performed to obtain the normal control sample submitted for TCGA. 3288147									
<u>50</u>	Other Method of Normal Sample Procurement		If the procedure performed to obtain the normal sample is not included in the provided list, specify the procedure. 3288151									
<u>51</u>	Month of Normal Sample Procurement		Provide the month of the procedure performed to obtain the normal control submitted for TCGA. 3288195									
<u>52</u>	Day of Normal Sample Procurement	$ \begin{array}{c ccccccccccccccccccccccccccccccccccc$	Provide the day of the procedure performed to obtain the normal control submitted for TCGA. 3288196									
<u>53</u>	Year of Normal Sample Procurement		Provide the year of the procedure performed to obtain the normal control submitted for TCGA. 3288197									
<u>54</u>	Normal Identifier		Provide the TSS unique normal ID. If multiple normal control samples are submitted, each normal control needs a unique ID. 3288138									
<u>55</u>	Anatomic Site of Non- Neoplastic Control Tissue	 Peritoneum Other (please specify)* 	If the normal control type is normal tissue, indicate the anatomic site of the non-neoplastic control tissue submitted for TCGA. 3081938 *Adjacent grossly normal pleura not acceptable.									
<u>56</u>	Other Site of Non- Neoplastic Control Tissue		If the normal control type is normal tissue and the anatomic site is not included in the provided list, specify the site of the non- neoplastic control. 3288189									
<u>57</u>	Proximity of Normal Tissue to Tumor	□ Distal (> 2cm) from the primary tumor	If the normal control type is normal tissue, confirm that the submitted normal tissue was at least 2cm away from the primary tumor. 3088708									
	-		Adjacent (< 2cm) Normal Tissue is not accepted for this tissue type. Unknown Normal Tissue is not acceptable for this tissue type.									
<u>58</u>	Normal Slide ID#		If the normal control type is normal tissue, provide the slide ID for the physical top slide OR the digital slide image of the normal control being sent to the BCR. 3288217									

quality controlled. **Pathology Review**

Review

TCGA metrics?

pathology report?

Ouestion

#

59

60

61

62

63

64

Initial Case Quality Control Form

Mesothelioma (MESO)

Entry Alternatives Working Instructions Verification: By providing the below information, the Principal Investigator acknowledges that the information provided by the institution is true and correct and has been Tissue Source Site (TSS) acknowledges that the Biospecimen Core Resource (BCR) may confirm that the diagnosis of the frozen biospecimen is consistent with the primary diagnosis reported by the TSS through histopathology examination in the BCR laboratory. If the BCR identifies a possible discrepancy, the TSS authorizes the BCR to report these patient results to the TSS by means of a formal report in confidential email format for the quality assurance program of the TSS to address. Provide the name of the Pathologist that provided Name of Pathologist the information for all previous sections. 3288225 Provide the date of the pathology review performed by the TSS Date of Pathologist pathologist above. 3288224 Principal Investigator/Authorized Designee Confirmation Confirm that the malignant sample submitted to the BCR meets the current tumor nuclei metrics for TCGA. □ Yes Percent Tumor Nuclei 3288520 meets TCGA metrics? \square No Check with the BCR to confirm the current acceptable TCGA metrics. Confirm that the malignant sample submitted to the BCR meets the current necrosis metrics for TCGA. Percent Necrosis meets □ Yes 3288524 \square No Check with the BCR to confirm the current acceptable TCGA metrics. Confirm that a de-identified pathology report will be sent to **De-Identified Pathology** □ Yes BCR prior to or with the shipment of the physical samples. **Report Submitted?** □ No 3288292 Confirm that the diagnosis provided on this CQCF for the tumor sample being submitted to TCGA is consistent with the diagnosis found on the patient's pathology report for the tumor being sent to the BCR. 3288300 If "yes," skip related question below. Is the histologic diagnosis The diagnosis is considered to be consistent if at least one of on the COCF (as determined the following criteria are met: by the TSS pathology review 1) Diagnosis on the CQCF is identical to the pathology report of the TCGA frozen section for the tumor being sent to the BCR. □ Yes 2) Diagnosis on the CQCF includes as least one of the subtypes top slide) consistent with \square No listed on the pathology report and all subtypes on the histology listed in the the pathology report are acceptable for TCGA. final diagnosis on the

3) Diagnosis on the CQCF is "histology, NOS" (i.e., Diffuse malignant mesothelioma, NOS) and the pathology report lists a specific subtype within the same histologic group Diagnosis on the COCE indicatos "Binhasis

4)	Diagnosis on the CQCF indicates "Biphasic mesothelioma" and
	the pathology report lists two or more acceptable
	subtypes, provided that percent subtype(s) meet
	applicable TCGA disease-specific requirements.

Initial Case Quality Control Form Mesothelioma (MESO)

#	Question	Entry Alternatives	Working Instructions
65	If the diagnosis on this form is not consistent with the provided pathology report, indicate the reason for the inconsistency.	 Macrodissection performed at TSS to select for a region containing an acceptable TCGA diagnosis (see note at right) Pathology analysis at TSS determined a specific histological subtype different from original pathology report (see note at right) Pathology review of frozen section for TCGA determined histological subtype different from the pathology report (see note at right) 	If the diagnosis provided on this form is not consistent with the diagnosis found on the pathology report provided, specify a reason for this inconsistency. 3288315 If a TSS pathology review of the TCGA committed sample resulted in a different histological subtype than what is documented on the original pathology report, an amendment to the pathology report should be submitted when the sample is shipped to the BCR; or in the absence of an amended pathology report, the TSS must complete and submit an electronic copy of the "TCGA Pathologic Diagnosis Discrepancy Form". In the case of diagnosis modifications, institution protocol should be followed for proper quality assurance.
66	History of Other Malignancy	 None History of Prior Malignancy History of Synchronous/ Bilateral Malignancy Both History of Synchronous/ Bilateral and Prior Malignancy 	Indicate whether the patient has a history of malignancies. If the patient has any history, including synchronous or bilateral malignancies, please complete an "Other Malignancy Form" for each malignancy diagnosed prior to the procurement of the tissue submitted for TCGA. 3382736 If the patient has a history of multiple diagnoses of basal or squamous cell skin cancer, complete an OMF for the first diagnosis for each of these types.
67	History of Neoadjuvant Treatment <i>for Tumor</i> <i>Submitted for TCGA</i>	 None Radiation prior to sample procurement* Pharmaceutical treatment prior to sample procurement* Both pharmaceutical treatment and radiation prior to sample procurement* 	Indicate whether the patient received therapy for this cancer prior to the sample procurement of the tumor submitted for TCGA . If the patient did receive treatment for this cancer prior to procurement, the TSS should contact the BCR for further instruction. 3382737 *Systemic therapy and certain localized therapies (those administered to the same site as the TCGA submitted tissue) given prior to the procurement of the sample submitted for TCGA are exclusionary.
68	Tobacco smoking history indicator	 1- Lifelong non-smoker (<100 cigarettes smoked in lifetime) 2- Current smoker (includes daily and non-daily smokers) 3- Current reformed smoker for > 15 years 4- Current reformed smoker for <= 15 years 5- Current reformed smoker (duration not specified) Smoking History not Documented 	Indicate the patient's history of tobacco smoking as well as their current smoking status using the defined categories. 2181650
69	Consent Status	□ Consented □ Exemption 4* □ Deceased □ Waiver*	Indicate whether the patient was formally consented, consented by death, or if the case has an exemption or waiver for consent. 3288361 *Exemptions and waivers for consent must be approved by NCI.
Date	e of Consent		
70	Month of Consent		If the patient was formally consented, provide the month of consent. 3081955

Initial Case Quality Control Form

V4.12 091812

Mesothelioma (MESO)

#	Question					F	ntry Alt	ernativ	96					Working Instructions
#	Question	_												
		$\Box 01$	$\Box 02$	$\Box 03$	$\Box 04$	$\Box 05$	$\Box 06$	$\Box 07$	$\Box 08$	$\Box 09$	$\Box 10$	□ 11	□ 12	If the patient was formally consented, provide the day
71	Day of Consent	□ 13	\Box 14	$\Box 15$	$\Box 16$	□ 17	$\Box 18$	□ 19	$\Box 20$	$\Box 21$	□ 22	□ 23	□ 24	of consent.
	2 ay of concerne	□ 25	□ 26	□ 27		□ 29						-		3081957
72	Year of Consent													If the patient was formally consented, provide the year of consent. 3081959
Dat	Date of Death Do not complete date of death, if patient formally consented.													
73	Month of Death	□ 01	□ 02	□ 03	□ 04	□ 05	□ 06	□ 07	□ 08	□ 09	□ 10	□ 11		If the patient consented by death, provide the month of death. 2897026
74	Day of Death	01 12	02	03	□ 04	05	□ 06	□ 07	□ 08	□ 09	□ 10	□ 11		If the patient consented by death, provide the day of death. 2897028
		□ 13	□ 14	□ 15	□ 16	□ 17	□ 18	□ 19	□ 20	□ 21	□ 22	□ 23		
75	Year of Death													If the patient consented by death, provide the year of death. 2897030
														_//

Principal Investigator or Designee Signature

Print Name

Date

I acknowledge that the above information provided by my institution is true and correct and has been quality controlled.